Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients—a case-control study
Autor: | Marc A. Benninga, Tim G. J. de Meij, Veronique L. Meester, Angelika Kindermann, Elsa A. van Wassenaer, Bart G. P. Koot |
---|---|
Přispěvatelé: | Amsterdam Reproduction & Development (AR&D), Pediatric surgery, AGEM - Digestive immunity, Graduate School, Paediatric Gastroenterology, AGEM - Re-generation and cancer of the digestive system |
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
Male
medicine.medical_specialty Adolescent Premedication 030226 pharmacology & pharmacy Inflammatory bowel disease Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine Humans Medicine Pharmacology (medical) 030212 general & internal medicine Child Infusions Intravenous Netherlands Pharmacology business.industry Incidence Incidence (epidemiology) Case-control study General Medicine Inflammatory Bowel Diseases medicine.disease Infliximab Injection Site Reaction Discontinuation Antirheumatic Agents Case-Control Studies Cohort Female Steroids business Intravenous steroids medicine.drug |
Zdroj: | van Wassenaer, E A, Meester, V L, Kindermann, A, Koot, B G P, Benninga, M A & de Meij, T G J 2019, ' Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients—a case-control study ', European Journal of Clinical Pharmacology, vol. 75, no. 10, pp. 1445-1450 . https://doi.org/10.1007/s00228-019-02715-z European Journal of Clinical Pharmacology, 75(10), 1445-1450. Springer Verlag European journal of clinical pharmacology, 75(10), 1445-1450. Springer Verlag |
ISSN: | 0031-6970 |
DOI: | 10.1007/s00228-019-02715-z |
Popis: | Purpose: Infusion reactions (IR) are commonly described side effects of infliximab (IFX) infusions, often leading to discontinuation of IFX. This study aimed to investigate the influence of steroid premedication (PM) on incidence of IR in pediatric inflammatory bowel disease (PIBD) patients receiving IFX. Methods: A case-control study in two tertiary centers in Amsterdam, The Netherlands, including PIBD patients receiving IFX. PM with steroids was part of standard care in one center (PM+) but not in the other center (PM−). Acute IR were divided into mild/severe reactions and in grade 1/2/3/4 for detailed exploration. Differences between subgroups were assessed with the T or chi-square test. Multivariate logistic regression was used to assess associations between PM and IR incidence, correcting for co-medication usage. Results: We included 226 patients (91 PM+, 50% male, mean age at onset of IBD 12.7 years), receiving 3433 infusions. There was no difference between the PM+ and PM− subgroups in incidence of IR (14.3% vs. 17.0% of patients, p = 0.58) and in percentage of infusions followed by IR (1.4% in both subgroups). The OR of developing IR when using PM was 1.06 (95% CI 0.49–2.27, p = 0.89), and the OR of developing a grade 3 or 4 IR when using PM was 0.90 (95% CI 0.24–3.39, p = 0.88) when correcting for co-medication usage. Conclusion: The incidence of IR was low, and premedication with steroids did not decrease the incidence of IR in this cohort of PIBD patients receiving IFX. Our results indicate that PM with steroids is not indicated in PIBD to prevent IR. |
Databáze: | OpenAIRE |
Externí odkaz: |